Compound News and Research

RSS

Babesiosis disease on the rise in Lower Hudson Valley: NYS DOH

Babesiosis, a rare and occasionally fatal tick-borne disease caused by microscopic parasites known as Babesia which infect red blood cells, is on the rise in the Lower Hudson Valley according to the NYS DOH, including the counties of Westchester, Putnam, Orange, Dutchess, Ulster, Sullivan and Rockland.

23 Jul 2010

New drug to treat chronic pain in SCD patients

A University of Minnesota Medical School research team led by Kalpna Gupta, Ph.D., has discovered that cannibinoids offer a novel approach to ease the chronic and acute pain caused by sickle cell disease.Using a mouse model of SCD, Gupta and University of Minnesota colleagues studied the pain mechanisms by observing animals that exhibited both musculoskeletal pain and temperature sensitivity, symptoms similarly experienced by humans with SCD. The team compared two classifications of drugs in their ability to manage pain sensed by the animals, the traditionally prescribed classification of drugs, opioids, with a new therapeutic approach, cannabinoids, a synthetic compound based on marijuana derivatives. Currently, the only approved treatment for management of severe pain in SCD is opioids.

23 Jul 2010

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.

22 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

Scientists discover world's first mass producible, low-cost organoclays for plastics

Scientists are reporting an in-depth validation of the discovery of the world's first mass producible, low-cost, organoclays for plastics. The powdered material, made from natural clay, would be a safer, more environmentally friendly replacement for the compound widely used to make plastics nanocomposites. A report on the research appears in ACS' Macromolecules, a bi-weekly journal.

22 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Pharmarama International, a leader in strategically sourcing comparator medicines for clinical trials worldwide, today announced that it has been ranked as Britain's eighth fastest-growing private company for overseas sales in a 2010 survey published by the country's leading business newspaper, The Sunday Times.

21 Jul 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

The flood of scientific evidence on omega-3 eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) has significantly buoyed the credibility of polyunsaturated fatty acids (PUFAs) as vital functional ingredients. Heightened consumer awareness has had a telling effect on the healthy growth charts of the marine and algae oil omega-3 ingredients market.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

20 Jul 2010

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

17 Jul 2010

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

As a national research university, Florida Institute of Technology not only involves its students in research, but also seeks to license and patent its many innovations. An example of recently licensed university technology is a chemical compound that facilitates the work of neuroscientists in the laboratory.Associate Professor Nasri Nesnas was familiar as a chemist with the chemical compound CDNI-Glu, a commonly used laboratory research tool. Most often, neuroscientists use it to study the brain's neural networks by improving the localization of synaptic stimulation

17 Jul 2010

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

17 Jul 2010

Research findings may help identify human TOR kinase inhibitors

A parasite estimated to afflict as many as 12 million people worldwide relies on a family of genes that should make it vulnerable to compounds developed to treat cancer and other disorders, researchers at Washington University School of Medicine in St. Louis have found.

17 Jul 2010

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

ALOKA CO., LTD., announced on July 16 the ProSound F75, a high-end color diagnostic ultrasound system of the new "F" series at its private exhibition, "Aloka Fair 2010." This new flagship of multi-purpose systems, providing unprecedented performance in a variety of clinical applications, is comfortable and easy to use.

16 Jul 2010

Scientists discover gene mutation responsible for CDG

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has discovered the gene mutation responsible for a condition in which eye and brain development is severely disrupted in affected infants.

16 Jul 2010

Compound News and Research

Babesiosis disease on the rise in Lower Hudson Valley: NYS DOH

New drug to treat chronic pain in SCD patients

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

Scientists discover world's first mass producible, low-cost organoclays for plastics

Affymetrix launches QuantiGene ViewRNA Assay formats

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Patent application for inexpensive CyPath assay filed by Biomoda

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

Resveratrol concentration impacts cancer risk mitigation: Study

Research findings may help identify human TOR kinase inhibitors

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

Scientists discover gene mutation responsible for CDG

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News